Related references
Note: Only part of the references are listed.Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain et al.
BLOOD (2015)
Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study
Eric Durot et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia
Sanne H. Tonino et al.
LEUKEMIA & LYMPHOMA (2015)
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison
I. Herth et al.
ANNALS OF ONCOLOGY (2014)
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
Constantine S. Tam et al.
BLOOD (2014)
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Peter Dreger et al.
BLOOD (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
Peter Dreger et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
Simon E. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Apostolia M. Tsimberidou et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: Long-term prospective multicenter study
Mauricette Michallet et al.
EXPERIMENTAL HEMATOLOGY (2013)
Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
J. R. Brown et al.
LEUKEMIA (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies
Sebastian Boettcher et al.
BLOOD REVIEWS (2011)
Nonmyeloablative Allogeneic Stem Cell Transplantation in Relapsed/Refractory Chronic Lymphocytic Leukemia Long-Term Follow-Up, Prognostic Factors, and Effect of Human Leukocyte Histocompatibility Antigen Subtype on Outcome
Issa F. Khouri et al.
CANCER (2011)
ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia
S. H. Tonino et al.
ONCOGENE (2011)
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Peter Dreger et al.
BLOOD (2010)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia
S. H. Tonino et al.
LEUKEMIA (2010)
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry
M. Michallet et al.
LEUKEMIA (2010)
Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia
Stephan Stilgenbauer et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation
Lucia Farina et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL:: a prospective randomized HOVON trial
Edo Vellenga et al.
BLOOD (2008)
Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
Mohamed L. Sorror et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
J. E. Castro et al.
LEUKEMIA (2008)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
P. Dreger et al.
LEUKEMIA (2007)
Cutting edge:: The phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25+Foxp3+ regulatory T cells
Daniel T. Patton et al.
JOURNAL OF IMMUNOLOGY (2006)
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
A. R. Pettitt et al.
LEUKEMIA (2006)
Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia
Carol Moreno et al.
BLOOD (2006)
High-risk fludarabine-pretreated B-Cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission
Ignazio Majolino et al.
MEDICAL ONCOLOGY (2006)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis
P Dreger et al.
LEUKEMIA (2005)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: Impact of rituximab on immunomodulation and survival
IF Khouri et al.
EXPERIMENTAL HEMATOLOGY (2004)
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation:: The Cooperative German Transplant Study Group
J Schetelig et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning
P Dreger et al.
LEUKEMIA (2003)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia
KC Doney et al.
BONE MARROW TRANSPLANTATION (2002)
Share Paper
